Reports Outline U.S. Military Medical Research Findings from Brooke Army Medical Center (The Benefit of Adjuvant Chemotherapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma Depends On Response To Neoadjuvant Therapy).

A recent study conducted at Brooke Army Medical Center in San Antonio, Texas, examined the benefit of adjuvant therapy (AT) following pancreaticoduodenectomy for pancreatic adenocarcinoma. The study found that the benefit of AT depends on the patient's response to neoadjuvant therapy (NAT). Patients who had a favorable response to NAT did not benefit from AT, while those who did not have a favorable response saw improved overall survival with AT. The study suggests that response to NAT should be considered when determining the need for AT in patients with pancreatic adenocarcinoma. [Extracted from the article]

Copyright of Gastroenterology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)